Doc, i don't know your background, but as a dexcom user (I have no stake in the company) I believe you're mistaken. first they actually have a brilliant business model the Animas pump from J&J is integrated with the Dexcom, the Omni Pod is working on it, where both the dexcom and pods will be controlled by smart phone. T:Slim by Tandem is awaiting FDA Clearance on their integrated G4 puump. accuracy of the g4 surpasses the medtronics cgm. many times I check the dexcom then take a blood test and the numbers are the same! They set themselves up that any pump company can develop an integrated pump as long as they conform to the dexcom standard, which means they will set the standard since they are not competing with the pump manufacturers.
No, medtronics cgm isn't nearly as accurate - and can't even read sugars on a smart phone or watch. I would have more to write if I wasn't typing this from my phone.
Exactly, big pharma is watching as in a buyout of Dexcom, not a matter of "if" but "when".
no. medtronics has the same CGM systems used in combination with the minimed pump. medtronics CGM system is there, but hasn't marketed it hard. There are lots of insurance coverage issues too. DXCM is a solid company. However, it is a one trick pony. MDT or others can really cause problems down the line. They have money to run trials. Besides, getting continuous monitoring is nice, but it is not a must. The market is a niche and small market where DXCM is in. It is nice to know your sugars throughout the day. However, What you do with the CGM data is the key point. That is why it is combined with an insulin pump. Old diabetics are not going to want to know it. It will be too scary or complicated for most old diabetics. Young diabetics are mostly insulin dependent and they want insulin pumps with CGM. I worry about this before I invest in DXCM. The analysts are pumping for their private clients. I have no positions at this time and DXCM is running up too much this year.
You are talking about very different devices - comparing apples with oranges.
you are in the state of euphoria. You forgot about minimed by mdt. minimed artificial pancreas sells way more than dxcm for years.
Dexcom's revenue growth has been a steady 60% for the last six quarters.
They have the only CGM device with FDA approval.
Their sensor gross margins are at 70%.
CGM eliminates conventional meters, strips, lancing devices.
Also eliminating the need for a patient draw blood, while giving true glucose levels not attainable with current strips and meters..
Bottom line Dexcom in the near future will dominate and own the 30 billion glucose monitoring industry.
The business of glucose monitoring is growing at a fast rate of 25% annually, and experts estimate that by 2017, the market will exceed $30 billion worldwide.
Dexcom's revenues have grown north of 60% annually for the last six quarters and their cash based income has increased threefold over the same quarter last year. Gross margins on their G4 Platinum sensor is between 70% and 75% and the gross margins for the hardware is 50% or better. Given that the data on the increasing level of new patients, their current retention rate and replacement hardware all looks positive, we continue to like how the company is positioned for growth. With two of the next generation sensors in development (the G5 and G6) we continue to believe DexCom will remain
Just about two weeks ago, Kevin Sayer spoke at the William Blair Conference on 6/9 - any investor or future investor in Dexcom should listen to the webcast; it is only 55 minutes long. This company is on solid footing and has enormous potential - just listen and decide for yourself. The presentation is under "Investor Relations" -- "Events and Presentations".
When you get to the point when you think your s--t doesn't stink, you have to get a reality check. It is increasingly likely that the very positive fundamental story is more than discounted in the current stock price. What do you think you know that the market doesn't? Really? You are more lucky than good, don't confuse the two.
Also to note, institutional ownership on DXCM is nearly 95% - several of these institutional investors have been in DXCM since it was under $40 pps and it is evident that they aren't selling (as a whole). This company will be bought out, it is not a matter of "if" but "when".
I am long and enjoying the ride. I have NO idea how high it will go or when. Assuming the tape stays (at least) benign, there seem to be lots of large buyers pushing the stock higher. No indication to believe the trend will change yet. Stock is very expensive but they have terrific technology. If you're worried, set a stop. Otherwise, relax and enjoy the run.
If you own this stock, given that it's making new all-time highs, its IMPOSSIBLE to be losing on it. Stock has a great product and is on a roll. WHY would you want to sell now? There is competition and like any technology, your biz can be obsolete very quickly. But, for the time being, nothing to worry about. Stock is very expensive but it remains a buyout candidate. Sit back. Enjoy the ride.
I am speculating but I would bet the recent run has to do with the numbers for next quarter.
As results come in they could be blowing projections out of the water.
My opinion DXCM easily breaks $80 after August earnings call.
Question will DXCM break $100 before the end of the year.
Remember they were priced at $33.00 on 6/13/14 about 1 year ago.
I surely would, however, at the moment, Dexcom is #1 in this arena and I would bank on it that Dexcom will stay ahead of the curve.
I own this stock and have made money on it. I notice that this message board is not very active but I'm wondering if anyone on it has a real knowledge of this company and it's future. Who are it's major competitors and whether it's really the time to get out. Let's discuss it professionally if you know anything.
All of you who have been with this stock for the last 2 years and made good money should now be thinking that this company has run it's race and is stagnating, it has gone as far as it can and made you good returns.
Now's it's time to move on to the next one and invest in $ECTE get in now while it's still under $2 you know it makes sense